PMVP insider filings
PMV Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-05. Screen PMVP transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Eckler Matthew Joseph — Director | 2 | — | — | 1 |
Recent insider filings — PMV Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-05 | 4 | Eckler Matthew Joseph — Director | Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2026-10-05 | 3 | Eckler Matthew Joseph — Director | Holdings only — no transactions reported | EDGAR |
| 2026-06-05 | 4 | FLOWERS KIRSTEN — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Stelzer Laurie — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | BAUM CHARLES M — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 42,000 (derivative) @ $0 · Gift (G): 42,000 (derivative) @ $0 · Gift (G): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LEVINE ARNOLD J — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Carulli Michael — Chief Financial Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Jalota Deepika — Chief Development Officer | Grant/award (A): 303,310 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Ticktin Robert — General Counsel & COO | Grant/award (A): 319,270 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Mack David Henry — President and CEO, Director | Grant/award (A): 744,960 (derivative) @ $0 | EDGAR |
| 2025-10-29 | 4 | Mack David Henry — President and CEO, Director | Option exercise (M): 220,643 @ $1.37 · Option exercise (M): 220,643 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP V LLC — 10% owner | Sale (S): 1,000,000 @ $1.52 | EDGAR |
| 2025-09-12 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP V LLC — 10% owner | Sale (S): 500,000 @ $1.80 | EDGAR |
| 2025-07-03 | 4 | Jalota Deepika — Chief Development Officer | Sale (S): 33,065 @ $1.06 | EDGAR |
| 2025-07-03 | 4 | Carulli Michael — Chief Financial Officer | Sale (S): 28,249 @ $1.06 | EDGAR |
| 2025-07-03 | 4 | Ticktin Robert — General Counsel & COO | Sale (S): 23,151 @ $1.06 | EDGAR |
| 2025-07-03 | 4 | Mack David Henry — President and CEO, Director | Sale (S): 58,411 @ $1.06 | EDGAR |
| 2025-06-09 | 4 | FLOWERS KIRSTEN — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Stelzer Laurie — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Heyman Richard A. — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BAUM CHARLES M — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 33,500 (derivative) @ $0 · Gift (G): 33,500 (derivative) @ $0 · Gift (G): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | LEVINE ARNOLD J — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Carulli Michael — Chief Financial Officer | Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Jalota Deepika — Chief Development Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Mack David Henry — President and CEO, Director | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Mack David Henry — President and CEO, Director | Option exercise (M): 91,750 @ $0.53 · Option exercise (M): 17,709 @ $0.53 · Option exercise (M): 91,750 (derivative) @ $0 · Option exercise (M): 17,709 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Jalota Deepika — Chief Development Officer | Disposition to issuer (D): 22,674 (derivative) · Disposition to issuer (D): 68,100 (derivative) · Grant/award (A): 90,774 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Grant/award (A): 125,000 (derivative) | EDGAR |
| 2024-10-03 | 4 | Carulli Michael — Chief Financial Officer | Disposition to issuer (D): 13,605 (derivative) · Disposition to issuer (D): 27,200 (derivative) · Grant/award (A): 40,805 (derivative) · Disposition to issuer (D): 75,000 (derivative) · Grant/award (A): 75,000 (derivative) | EDGAR |
| 2024-10-03 | 4 | Mack David Henry — President and CEO, Director | Disposition to issuer (D): 134,584 (derivative) · Disposition to issuer (D): 249,600 (derivative) · Grant/award (A): 384,184 (derivative) · Disposition to issuer (D): 330,000 (derivative) · Grant/award (A): 330,000 (derivative) | EDGAR |
| 2024-09-12 | 4 | Jalota Deepika — Chief Development Officer | Sale (S): 7,218 @ $1.50 | EDGAR |
| 2024-09-12 | 4 | Carulli Michael — Chief Financial Officer | Sale (S): 2,891 @ $1.50 | EDGAR |
| 2024-06-10 | 4 | FLOWERS KIRSTEN — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Stelzer Laurie — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Heyman Richard A. — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | BAUM CHARLES M — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 67,500 (derivative) @ $0 · Gift (G): 67,500 (derivative) @ $0 · Gift (G): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | LEVINE ARNOLD J — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Jalota Deepika — Chief Development Officer | Grant/award (A): 95,555 @ $0 · Grant/award (A): 225,095 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Carulli Michael — Chief Financial Officer | Grant/award (A): 82,220 @ $0 · Grant/award (A): 204,630 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Mack David Henry — President and CEO, Director | Grant/award (A): 163,890 @ $0 · Grant/award (A): 519,915 (derivative) @ $0 | EDGAR |
| 2023-11-24 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP V LLC — 10% owner OrbiMed Genesis GP LLC — 10% owner | Sale (S): 87,786 @ $2.23 | EDGAR |
| 2023-11-13 | 4 | Mack David Henry — President and CEO, Director | Option exercise (M): 198,407 @ $0.53 · Gift (G): 85,307 @ $0 · Gift (G): 85,307 @ $0 · Option exercise (M): 198,407 (derivative) @ $0 | EDGAR |
| 2023-09-18 | 4 | Jalota Deepika — Chief Development Officer | Sale (S): 4,104 @ $6.62 | EDGAR |
| 2023-09-18 | 4 | Alland Leila — Chief Medical Officer | Sale (S): 6,291 @ $6.62 | EDGAR |
| 2023-08-08 | 4 | Mack David Henry — President and CEO, Director | Option exercise (M): 85,500 @ $0.53 · Option exercise (M): 85,500 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | BAUM CHARLES M — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 21,500 (derivative) @ $0 · Gift (G): 21,500 (derivative) @ $0 · Gift (G): 21,500 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | LEVINE ARNOLD J — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — PMV Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PMVP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs